The charges allege that Biohaven submitted false claims to Medicare ... so they would preferentially prescribe the company’s migraine drug Nurtec ODT (rimegepant). A kickback is a negotiated ...

Four Colorado physicians are named in a lawsuit settlement involving pharmaceutical company Biohaven, which allegedly paid ...

Shares of Biohaven Ltd. climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological ...

According to GlobalData, Qulipta has the edge when it comes to data on migraine ... virus (RSV) drug developer ReVIral last month. The company said it expects the Biohaven deal to close by early ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ...

November 25, 2024 Biohaven's spinal muscular atrophy drug fails to meet study goal Biohaven said on Monday its experimental treatment for a rare neuromuscular disorder failed to significantly ...

Biohaven's antibody drug conjugate (ADC ... advancing enrollment in proof of concept trial with BHV-2100 in acute migraine; data from the laser-evoked potential study expected in 1H 2025.